Chronic Cough — Med2Date

📋 Key Information Summary

📋

Chronic cough is defined as a cough persisting for ≥8 weeks in adults and ≥4 weeks in children, affecting up to 10% of the Australian adult population.
The three most common causes in non-smokers with a normal chest X-ray are upper airway cough syndrome (UACS), asthma/Cough-variant asthma, and gastro-oesophageal reflux disease (GORD) — responsible for up to 90% of cases.
Eosinophilic bronchitis (sputum eosinophilia without airflow obstruction) accounts for 10–30% of referrals to cough clinics and responds to inhaled corticosteroids.
ACE inhibitor–induced cough affects 5–35% of patients on ACE inhibitors; switch to an ARB and allow 4 weeks for resolution.
A stepwise diagnostic workup begins with chest X-ray and spirometry with bronchodilator reversibility, followed by FeNO, induced sputum eosinophils, and CT chest where indicated.
Empiric sequential treatment trials (first UACS, then asthma, then GORD) are an accepted diagnostic strategy when initial investigations are non-diagnostic.
Red flags requiring urgent referral: haemoptysis, significant weight loss, new cough in a smoker aged >45 years, stridor, lymphadenopathy, or suspected foreign body.
Inhaled corticosteroids (e.g. fluticasone propionate 250–500 µg BD) are the mainstay of therapy for cough-variant asthma and eosinophilic bronchitis; PPI therapy for GORD-related cough.
Refractory chronic cough (cough persisting despite optimal treatment of all identified causes) is increasingly recognised as cough hypersensitivity syndrome (CHS).
For refractory cough: speech pathology/behavioural therapy (level 1 evidence), gabapentin 300–1800 mg/day, pregabalin 150–300 mg/day, or the P2X3 antagonist gefapixant 45 mg BD (PBS Authority Required, listed 2024).
Consider Aboriginal and Torres Strait Islander communities: higher prevalence of bronchiectasis, chronic suppurative lung disease, environmental exposures, and barriers to specialist access in remote regions.
Always review medication lists for ACE inhibitors and check adherence/prescribing errors. A systematic, protocol-driven approach (Morice et al. ERJ 2020) achieves diagnosis in >90% of cases.

Introduction & Australian Epidemiology

Chronic cough is one of the most common presentations to Australian general practice, accounting for an estimated 2–3 million consultations annually. It is defined in adults as a cough persisting for ≥8 weeks; in children, the threshold is ≥4 weeks. The condition places a substantial burden on quality of life, sleep, continence, social functioning, and workplace productivity.

Australian population data suggest a prevalence of 9–12% among adults, with higher rates among women (2:1 female-to-male ratio in specialist cough clinics), older adults, and Aboriginal and Torres Strait Islander populations, in whom chronic suppurative lung disease and bronchiectasis remain highly prevalent.

In approximately 90% of immunocompetent, non-smoking adults with a normal chest X-ray, chronic cough is attributable to one or more of three conditions: upper airway cough syndrome (UACS), asthma (including cough-variant asthma), and gastro-oesophageal reflux disease (GORD). Eosinophilic bronchitis and medication-related cough (particularly ACE inhibitors) account for most of the remainder.

A structured, evidence-based approach — combining targeted history, examination, investigation, and sequential empiric therapy — achieves a specific diagnosis in over 90% of patients. Australian respiratory specialists and the Thoracic Society of Australia and New Zealand (TSANZ) advocate a protocol-driven algorithm modelled on the European Respiratory Society (ERS) 2020 guidelines, adapted to the Australian healthcare context including PBS availability, MBS item numbers, and access to specialist cough clinics.

⚠️

Scope note: This guideline covers chronic cough in immunocompetent adults. Chronic cough in immunocompromised patients (HIV, transplant, chemotherapy), children <15 years, and acute/subacute cough (<8 weeks) are addressed in separate guidelines.

Evaluation & Causes

Defining Chronic Cough

Chronic cough is defined as a cough lasting ≥8 weeks in adults. Subacute cough (3–8 weeks) most commonly follows upper respiratory tract infection and is self-limiting; however, it warrants investigation if it fails to resolve. The aetiological approach to chronic cough differs fundamentally from acute cough.

The Three Common Causes

✅

In immunocompetent, non-smoking adults with a normal chest X-ray, one or more of three conditions accounts for approximately 90% of chronic cough. A systematic approach to these three diagnoses should be the starting point of every evaluation.

1. Upper Airway Cough Syndrome (UACS) — formerly "Post-nasal Drip Syndrome"

UACS is the single most common cause of chronic cough, implicated in 20–40% of cases. It arises from conditions affecting the nose, sinuses, and pharynx that stimulate afferent cough receptors in the upper airway.

Common aetiologies: Allergic rhinitis, perennial non-allergic rhinitis, vasomotor rhinitis, chronic sinusitis (with or without nasal polyps), post-infectious rhinitis.
Clinical features: Sensation of post-nasal drip, nasal congestion, rhinorrhoea, frequent throat clearing, cobblestone pharyngeal mucosa, mucus in the oropharynx. However, many patients are unaware of nasal symptoms — a history of post-nasal drip is absent in up to 50% of cases confirmed at specialist cough clinics.
Diagnostic approach: Clinical response to empiric first-generation antihistamine/decongestant combination therapy (e.g. loratadine + pseudoephedrine, or brompheniramine + pseudoephedrine) serves as both diagnostic trial and treatment. Sinus CT is reserved for suspected chronic rhinosinusitis.

2. Asthma and Cough-Variant Asthma

Asthma accounts for 25–30% of chronic cough cases. Cough-variant asthma is a phenotype in which cough is the sole or predominant symptom, without the classic triad of wheeze, dyspnoea, and chest tightness.

Clinical features: Cough worse at night or in the early morning, triggered by cold air, exercise, allergens, or respiratory infections. May be seasonal.
Diagnostic criteria: Demonstration of variable airflow obstruction on spirometry (≥12% and ≥200 mL improvement in FEV₁ post-bronchodilator), positive methacholine challenge (PC₂₀ <8 mg/mL), elevated exhaled nitric oxide (FeNO ≥40 ppb in adults), or sputum eosinophilia (≥3%). A positive response to empiric inhaled corticosteroid trial is supportive.
Important distinction: Cough-variant asthma and eosinophilic bronchitis overlap clinically; the key difference is normal spirometry and no bronchial hyperresponsiveness in eosinophilic bronchitis.

3. Gastro-Oesophageal Reflux Disease (GORD)

GORD is implicated in 10–20% of chronic cough cases. The relationship is complex — cough can cause reflux (via transient lower oesophageal sphincter relaxation) and reflux can cause cough (via vagal-mediated oesophago-bronchial reflex and micro-aspiration).

Clinical features: Heartburn, regurgitation, cough worse after meals or when supine, waterbrash. However, up to 75% of patients with GORD-related cough have no typical reflux symptoms ("silent reflux").
Diagnostic approach: Empiric PPI trial (e.g. esomeprazole 40 mg BD for ≥8 weeks) is the recommended initial strategy. Ambulatory pH-impedance monitoring (MBS item 32222) is reserved for refractory cases or where anti-reflux surgery is being considered.
Key point: GORD should only be assigned as a cause of chronic cough when cough improves or resolves with anti-reflux therapy.

Other Important Causes

Cause	Proportion	Key Features	Diagnostic Test
Eosinophilic bronchitis	10–30%	Cough with sputum eosinophilia, normal spirometry, no bronchial hyperresponsiveness	Induced sputum eosinophils ≥3%
ACE inhibitor cough	5–35% of ACEi users	Dry, tickly cough; onset days to months after starting ACEi; more common in women and patients of East Asian descent	Resolution after ACEi cessation (allow 4 weeks)
Chronic bronchitis/COPD	5–10%	Productive cough ≥3 months/year for ≥2 consecutive years; current or ex-smoker	Spirometry showing fixed airflow obstruction
Bronchiectasis	Up to 30% in ATSI populations	Chronic productive cough, recurrent infections, coarse crackles	HRCT chest
Lung malignancy	<2%	New cough in smoker >45 yrs, haemoptysis, weight loss, clubbing	CT chest ± bronchoscopy
Post-infectious cough	Common (<8 weeks, may persist)	Following URTI; Bordetella pertussis, Mycoplasma, Chlamydophila	Serology, PCR nasopharyngeal aspirate
Interstitial lung disease	Variable	Dry cough, progressive dyspnoea, bibasal crackles, restrictive defect	HRCT, PFTs, autoimmune serology
Obstructive sleep apnoea	Emerging data	Nocturnal cough, snoring, daytime somnolence	Polysomnography

🚨

Red flags for malignancy or serious pathology: Haemoptysis, significant unintentional weight loss (>5%), new cough in a current or ex-smoker aged >45 years, stridor, dysphagia, new lymphadenopathy, systemic symptoms (fever, night sweats), clubbing, or unilateral wheeze. These warrant urgent CT chest and specialist referral within 2 weeks.

Diagnostic Workup

Initial Assessment in General Practice

A thorough history and targeted examination form the foundation of the diagnostic workup. The initial assessment should systematically address red flags, medication review, occupational/environmental exposures, and features of the three common causes.

History — Key Elements

Cough character: Dry vs. productive, timing (nocturnal, postprandial), triggers (cold air, exercise, talking, eating, position), duration, and progression.
Associated symptoms: Rhinorrhoea, nasal congestion, heartburn, regurgitation, wheeze, dyspnoea, sputum colour/volume, haemoptysis.
Medication review: ACE inhibitors (any duration), beta-blockers, and rarely inhaled medications.
Smoking history: Pack-years, current status, passive exposure.
Occupational history: Exposure to dusts, chemicals, fumes; isocyanate exposure; farming/animal contact.
Atopic history: Personal/family history of asthma, eczema, allergic rhinitis.
Impact on quality of life: The Leicester Cough Questionnaire (LCQ) provides a validated symptom score.

First-Line Investigations

Essential Chest X-ray (PA and lateral) MBS item 58110 — All patients with chronic cough. Assess for mass lesion, consolidation, interstitial changes, bronchiectasis, pleural effusion. Normal CXR in the majority of uncomplicated chronic cough.

Essential Spirometry with bronchodilator reversibility MBS item 11506 (if performed in practice) or referral to respiratory laboratory (MBS item 11503). Assess FEV₁, FVC, FEV₁/FVC ratio. ≥12% and ≥200 mL improvement in FEV₁ post-salbutamol supports asthma diagnosis.

Available Fractional Exhaled Nitric Oxide (FeNO) Available in respiratory function laboratories. FeNO ≥40 ppb in adults suggests eosinophilic airway inflammation (asthma or eosinophilic bronchitis). Highly specific but moderate sensitivity. Not yet MBS-rebated but widely accessible.

Available Full blood count with differential MBS item 65070 — Peripheral eosinophilia (>0.5 × 10⁹/L) supports allergic/eosinophilic aetiology. Also screens for anaemia and infection markers.

Available Total IgE and specific IgE (skin prick or RAST) MBS item 65590 (IgE). Assess for atopic status; allergen-specific testing if allergic rhinitis suspected as cause of UACS.

Second-Line Investigations

Referral Methacholine / mannitol bronchial provocation challenge MBS item 11512 (specialist respiratory laboratory). Indicated when spirometry is normal but asthma is suspected. PC₂₀ <8 mg/mL or PD₂₀ <100 µg (mannitol) confirms bronchial hyperresponsiveness. Accessible in most metropolitan centres; availability limited in regional/remote areas.

Referral Induced sputum eosinophil count Specialist cough clinic or respiratory laboratory. Sputum eosinophils ≥3% confirms eosinophilic bronchitis. Requires hypertonic saline nebulisation and experienced cytology processing. Limited availability — primarily tertiary centres.

Referral HRCT chest MBS item 56302 — High-resolution CT for suspected bronchiectasis, ILD, or structural abnormality not visible on CXR. Indicated if productive cough, recurrent infections, or red flags present.

Referral Ambulatory 24-hour pH-impedance monitoring MBS item 32222 — Gastroenterology. Quantifies acid and non-acid reflux events. Indicated when GORD-related cough is refractory to PPI therapy or when anti-reflux surgery is considered.

Specialist Flexible bronchoscopy with BAL MBS item 38412 — Respiratory physician. Reserved for suspected endobronchial lesion, foreign body, or when other investigations are non-diagnostic. BAL cell differential can identify eosinophilic, neutrophilic, or lymphocytic patterns.

Specialist 24-hour cough monitoring (objective cough frequency) Leicester Cough Monitor or VitaloJAK — primarily available in specialist cough clinics for research or refractory cases. Quantifies cough frequency to objectively monitor treatment response.

Empiric Treatment Trials

When initial investigations do not reveal a clear diagnosis, sequential empiric treatment trials are an accepted and guideline-recommended diagnostic strategy. Each trial should be of sufficient duration and dose before assessing response.

1

Trial 1 — UACS

First-generation antihistamine/decongestant (e.g. brompheniramine + pseudoephedrine) or intranasal corticosteroid (e.g. mometasone furoate 200 µg daily) for 2–4 weeks. If cough improves → UACS confirmed.

2

Trial 2 — Asthma/Cough-Variant Asthma

Inhaled corticosteroid (e.g. fluticasone propionate 250–500 µg BD via spacer) for 4–8 weeks. If cough improves → cough-variant asthma or eosinophilic bronchitis confirmed.

3

Trial 3 — GORD

Double-dose PPI (e.g. esomeprazole 40 mg BD) + lifestyle measures for ≥8 weeks. If cough improves → GORD-related cough. Note: response may be delayed up to 3 months.

Specialty Referral Indications

⚠️

Refer to a respiratory physician or specialist cough clinic when: (1) red flags are present, (2) chest X-ray is abnormal, (3) cough persists despite sequential empiric treatment trials, (4) suspected bronchiectasis or ILD, (5) objective cough assessment is needed, or (6) a neuromodulator or novel therapy (gefapixant) is being considered. Most Australian tertiary hospitals have dedicated cough clinics — Royal Prince Alfred, Alfred Health, John Hunter, Sir Charles Gairdner, Royal Adelaide.

Treatment Strategies

The cornerstone of chronic cough management is treating the underlying cause(s). Up to 25% of patients have multiple concurrent causes, each of which must be addressed simultaneously. Treatment should follow a systematic, stepwise approach with regular reassessment.

Treatment of Specific Causes

Upper Airway Cough Syndrome

💊

Mometasone Furoate nasal spray

Nasonex® · Intranasal corticosteroid

Adult dose 200 µg (2 sprays each nostril) once daily

Duration Minimum 4 weeks; ongoing if chronic rhinosinusitis

Renal adjustment None required

PBS status ✔ PBS General Benefit

💊

Loratadine + Pseudoephedrine

Claratyne-D® · Antihistamine/decongestant

Adult dose Loratadine 5 mg / pseudoephedrine 120 mg (modified release) BD

Duration 2–4 weeks diagnostic trial

Renal adjustment Use with caution in severe renal impairment

PBS status ✘ Not PBS (OTC)

Cough-Variant Asthma and Eosinophilic Bronchitis

💊

Fluticasone Propionate

Flixotide® · Inhaled corticosteroid

Adult dose 250–500 µg BD via MDI + spacer or DPI

Duration Minimum 8 weeks; step down once cough controlled

Paediatric dose 100–200 µg BD (age ≥4 years)

Renal adjustment None required

PBS status ✔ PBS General Benefit

💊

Budesonide

Pulmicort® · Inhaled corticosteroid

Adult dose 400–800 µg BD via Turbuhaler®

Duration Minimum 8 weeks

Renal adjustment None required

PBS status ✔ PBS General Benefit

💊

Prednisolone (short course for severe eosinophilic bronchitis)

Panafcortelone® · Oral corticosteroid

Adult dose 30–40 mg PO daily for 7–14 days then taper

Duration 7–14 days; not for long-term use as cough therapy

Renal adjustment None required

PBS status ✔ PBS General Benefit

ACE Inhibitor–Induced Cough

✅

Switch to an ARB (e.g. losartan 50–100 mg daily, irbesartan 150–300 mg daily). Allow up to 4 weeks for cough to resolve after ceasing the ACE inhibitor. All ACE inhibitors share this class effect; switching to another ACE inhibitor is not effective.

GORD-Related Cough

💊

Esomeprazole

Nexium® · Proton pump inhibitor

Adult dose 40 mg PO BD (double dose) — 30 min before meals

Duration Minimum 8 weeks; up to 3 months for cough response

Renal adjustment No adjustment required (avoid in severe hepatic impairment >Child-Pugh B)

PBS status ✔ PBS General Benefit

Lifestyle measures should accompany PPI therapy: weight loss (if BMI >25), elevation of bedhead (15–20 cm), avoidance of late meals (≥3 hours before lying down), reduction of alcohol, caffeine, chocolate, and fatty foods. Alginate-based therapies (e.g. Gaviscon Advance®) may provide additional benefit for non-acid reflux.

Adjunctive and Supportive Therapies

Speech Pathology / Behavioural Cough Suppression Therapy

Speech pathology-led cough suppression therapy (CST) is an evidence-based intervention with Level 1 evidence (randomised controlled trials). It involves education on cough suppression techniques, breathing pattern retraining, voluntary cough control, and psychoeducation about the cough hypersensitivity cycle.

Components: Education on the cough cycle, controlled breathing techniques (slow, low breathing through the nose), voluntary cough suppression ("the natural urge suppression technique"), hydration and vocal hygiene, and identification/management of laryngeal irritants.
Efficacy: RCTs show a 40–60% reduction in cough frequency; comparable to pharmacotherapy with fewer side effects.
Access: Available through hospital outpatient speech pathology departments and some private practices. Medicare rebate via GP Management Plan (MBS item 721) and Team Care Arrangement (MBS item 723) — up to 5 allied health sessions per year under Medicare.
Telehealth: Increasingly delivered via telehealth, which is particularly valuable for patients in regional and remote Australia.

Other Adjunctive Measures

Smoking cessation: Essential. Offer NRT, varenicline (Champix®), or bupropion. Refer to Quitline (13 7848).
Environmental modification: Occupational dust/mask exposure — workplace health assessment; allergen avoidance for allergic patients.
Hydration: Adequate fluid intake; steam inhalation may provide temporary symptomatic relief.
Avoid over-the-counter cough suppressants: Codeine, dextromethorphan, and antitussives have limited evidence in chronic cough and carry risk of dependence and side effects.

Refractory Chronic Cough

Definition and Concept

Chronic cough is classified as refractory when it persists despite systematic investigation and treatment of all identified causes. It is important to distinguish:

Refractory chronic cough: Cough persisting despite treatment of identified causes.
Unexplained chronic cough: Cough persisting despite thorough evaluation with no identifiable cause.

Both categories are increasingly understood through the lens of cough hypersensitivity syndrome (CHS).

Cough Hypersensitivity Syndrome (CHS)

CHS is a clinical concept endorsed by the ERS (2020) describing a condition characterised by exaggerated cough response to low-level stimuli (cold air, talking, laughing, strong odours, eating dry food) that would not normally provoke cough. The underlying mechanism involves:

Peripheral sensitisation: Upregulation of vagal afferent nerve receptors (particularly P2X3 receptors on C-fibre afferents) in the larynx, trachea, and bronchi. ATP acting on P2X3 receptors is a key mediator of the urge-to-cough sensation.
Central sensitisation: Enhanced processing of cough signals in the brainstem nucleus tractus solitarius and higher cortical centres, analogous to central sensitisation in chronic pain syndromes.
Neuroplasticity: Persistent cough becomes self-perpetuating — the cough itself causes airway inflammation and mucosal damage, which further drives peripheral sensitisation.
Female predominance: The 2:1 female-to-male ratio in chronic cough clinics may relate to sex differences in cough reflex sensitivity (hormonal influences, ACE2 expression).

💡

Parallels with chronic pain: CHS is increasingly viewed as a sensory neuropathy of the vagal afferent system, sharing mechanisms with chronic pain (peripheral/central sensitisation, neuroplasticity, wind-up). This understanding has driven the development of neuromodulator therapies targeting these pathways.

Pharmacotherapy for Refractory Chronic Cough

Neuromodulators

💊

Gabapentin

Neurontin® · Gabapentinoid / neuromodulator

Mechanism α2δ calcium channel subunit ligand; reduces central sensitisation of vagal afferents

Adult dose Start 300 mg PO OD, titrate by 300 mg every 3–5 days; target 600 mg BD (range 300–1800 mg/day in divided doses)

Duration Minimum 8 weeks at target dose; reassess at 12 weeks. Taper over 1–2 weeks to cease (do not stop abruptly)

Side effects Drowsiness, dizziness, peripheral oedema, weight gain. Slow titration minimises adverse effects.

Renal adjustment eGFR 30–59: max 600 mg/day; eGFR 15–29: max 300 mg/day; eGFR <15: 300 mg alternate days; HD: 300 mg post-dialysis

PBS status ⚠ PBS Authority Required (for neuropathic pain; cough is off-label)

💊

Pregabalin

Lyrica® · Gabapentinoid / neuromodulator

Mechanism α2δ calcium channel subunit ligand; similar mechanism to gabapentin with more predictable pharmacokinetics

Adult dose Start 75 mg PO BD; titrate to 150 mg BD after 1 week

Duration Minimum 8 weeks; reassess at 12 weeks

Side effects Drowsiness, dizziness, weight gain, peripheral oedema, blurred vision

Renal adjustment eGFR 30–59: max 300 mg/day; eGFR 15–29: max 150 mg/day; eGFR <15: 75 mg/day

PBS status ⚠ PBS Authority Required (for neuropathic pain; cough is off-label)

💊

Amitriptyline

Endep® · Tricyclic antidepressant / neuromodulator

Mechanism Serotonin/noradrenaline reuptake inhibition; central neuromodulation of cough reflex

Adult dose Start 10 mg PO nocte; titrate to 25–50 mg nocte

Duration Minimum 8 weeks

Side effects Anticholinergic effects (dry mouth, constipation, urinary retention), sedation, weight gain, cardiac arrhythmia risk

Renal adjustment None required; use with caution

PBS status ✔ PBS General Benefit

P2X3 Antagonists — Targeted Peripheral Therapy

🆕

Gefapixant (brand name Lyfnua®) is the first-in-class selective P2X3 receptor antagonist specifically developed for refractory chronic cough. It was approved by the TGA in 2023 and listed on the PBS in 2024 as an Authority Required item. This represents a paradigm shift — the first therapy specifically approved for chronic cough in Australia.

💊

Gefapixant

Lyfnua® · P2X3 receptor antagonist

Mechanism Selective P2X3 receptor antagonist; blocks ATP-mediated activation of vagal C-fibre afferents in the airway, reducing the urge-to-cough signal. Does not cross the blood-brain barrier — purely peripheral action.

Adult dose 45 mg PO BD (with food)

Efficacy COUGH-1 and COUGH-2 trials: 24-hour cough frequency reduced by ~18% vs placebo at 45 mg BD. Clinically meaningful improvement in 50–60% of patients.

Side effects Taste alteration (dysgeusia) in ~60% of patients (the most common adverse effect and reason for cessation). Generally mild–moderate; may improve over weeks. Altered taste for bitter, sweet, and savoury foods. Rare: headache, nausea.

Renal adjustment eGFR 15–29: 45 mg OD; eGFR <15 or HD: not recommended

Hepatic adjustment Mild (Child-Pugh A): no adjustment; Moderate–Severe (Child-Pugh B–C): not recommended

PBS status ⚠ PBS Authority Required — For refractory or unexplained chronic cough (≥8 weeks) in adults who have had a comprehensive workup by a respiratory specialist, with documented failure of treatment for underlying causes. Prescribing restricted to respiratory physicians.

⚠️

Gefapixant prescribing note: PBS Authority Required — initial approval for 12 months. Patient must have undergone evaluation by a respiratory specialist with exclusion/treatment of common causes. Prescriber must be a respiratory specialist or thoracic physician. Taste disturbance is expected; counsel patients before initiation. Review response at 12 weeks.

Other Agents (Limited Evidence)

Low-dose morphine: 2.5–5 mg PO BD (modified release). Evidence from small RCTs showing benefit. Used cautiously due to dependence risk, constipation, and respiratory depression. PBS Authority Required (for palliative care; off-label for cough).
Speech pathology/behavioural cough suppression therapy: Should be offered to ALL patients with refractory cough, either alone or in combination with pharmacotherapy. Level 1 evidence, no side effects.
Proton pump inhibitors (high-dose, prolonged): Even without clear GORD symptoms, some cough specialists trial extended PPI courses (3–6 months) given the high prevalence of "silent" reflux. Evidence remains debated.
Inhaled corticosteroid/nebulised lidocaine: Case series support short-term benefit with nebulised lignocaine 2% (2–4 mL BD) for severe refractory cough; access via specialist cough clinic only.

Behavioural and Psychological Interventions

For patients with refractory cough, the interplay between psychological factors (anxiety, depression, catastrophising) and cough hypersensitivity should be addressed:

Speech pathology-led CST (as above) — first-line non-pharmacological intervention.
Cognitive behavioural therapy (CBT) — emerging evidence for addressing the psychosocial impact of chronic cough and modifying illness beliefs.
Mindfulness-based stress reduction — may help with central sensitisation and hypervigilance to cough.
Support groups: Lung Foundation Australia offers patient resources and peer support for chronic respiratory conditions.

Monitoring

Monitoring Framework

Baseline

Comprehensive assessment, Leicester Cough Questionnaire (LCQ), CXR, spirometry ± FeNO. Document cough severity and impact on quality of life. Review medication list (ACE inhibitors). Assess smoking status.

4 weeks

Reassess response to first empiric trial (UACS therapy). If no improvement, proceed to next empiric trial (asthma therapy). Monitor for treatment side effects.

8 weeks

Reassess response to second empiric trial (inhaled corticosteroid). Repeat LCQ. If cough persists, consider third empiric trial (PPI for GORD) and/or refer to respiratory specialist.

12–16 weeks

If cough persists despite all empiric trials → classify as refractory chronic cough. Specialist referral for cough clinic assessment, bronchial provocation testing, induced sputum, HRCT as indicated.

6 months

If on neuromodulator (gabapentin/pregabalin) or gefapixant: reassess efficacy, side effects, LCQ score. Consider dose adjustment or switching. Continue speech pathology if available.

12 months

Comprehensive review. Consider step-down of therapy if cough controlled. Repeat spirometry if previously abnormal. Review PBS authority renewal for gefapixant. Re-evaluate for new/different diagnoses.

Objective Assessment Tools

Tool	Type	Details	Use
Leicester Cough Questionnaire (LCQ)	Patient-reported outcome	19-item validated tool; physical, psychological, and social domains. Score range 3–21; higher = better. Minimum clinically important difference (MCID) = 1.3 points.	Baseline and serial monitoring
Visual Analogue Scale (VAS)	Patient-reported outcome	0–100 mm scale for cough severity. Quick to administer. MCID = 17 mm.	Clinic visits; quick assessment
Cough Severity Diary (CSD)	Patient-reported outcome	7-item daily diary; validated for clinical trials. Captures day-to-day variability.	Clinical trials and specialist assessment
24-hour cough monitoring	Objective	Leicester Cough Monitor or VitaloJAK ambulatory recording device. Cough frequency (coughs/hour). MCID = not yet standardised for clinical use.	Specialist cough clinics; clinical trials

Special Populations

🤰 Pregnancy

Inhaled corticosteroids: Budesonide is the preferred ICS in pregnancy (Category A). Use at lowest effective dose. Fluticasone propionate (Category B3) is an alternative.

PPIs: Pantoprazole is the preferred PPI in pregnancy (Category B3). Omeprazole has more safety data but is Category B3. Avoid esomeprazole (limited data).

Antihistamines: Loratadine (Category B1) is preferred. Avoid first-generation antihistamines near term.

Gabapentin/pregabalin: Contraindicated — Category B3 (limited data; teratogenicity signals in animal studies). Avoid.

Gefapixant: No pregnancy safety data. Not recommended in pregnancy or breastfeeding.

Physiological changes in pregnancy (reduced FRC, elevated diaphragm, mucosal oedema) may worsen cough. GORD is common in pregnancy and may contribute. Speech pathology therapy is safe and effective at all gestations.

👶 Paediatrics

Definition: Chronic cough in children is defined as lasting ≥4 weeks (different from adults). Wet/productive cough has a different differential from dry cough in children.

Common causes (children): Protracted bacterial bronchitis (PBB) is the most common cause of chronic wet cough in children and responds to 2–4 weeks of antibiotics (amoxicillin-clavulanate). Asthma, UACS, and GORD are also common.

Red flags (children): Chronic wet cough with daily sputum production, clubbing, failure to thrive, recurrent lower respiratory infections → suspect bronchiectasis. Urgent HRCT and respiratory specialist referral.

Pharmacotherapy limitations: Gabapentin, pregabalin, and gefapixant are not approved for use in children <18 years for cough.

Refer to TSANZ/ERS guidelines for chronic cough in children. Speech pathology CST has paediatric-adapted protocols with emerging evidence.

👴 Elderly (≥65 years)

ACE inhibitor cough: Higher prevalence in elderly patients due to increased ACE inhibitor prescribing for cardiovascular and renal indications. Always review medication list.

Neuromodulators: Use gabapentin/pregabalin with caution — increased risk of drowsiness, falls, dizziness, cognitive impairment. Start at lower doses and titrate more slowly.

Aspiration risk: In elderly patients with neurological conditions (stroke, Parkinson's disease, dementia), chronic cough may reflect aspiration. Consider videofluoroscopic swallowing study.

COPD overlap: Many elderly patients have concurrent COPD with a chronic productive cough component. Ensure optimal COPD management (smoking cessation, inhaler therapy, pulmonary rehabilitation).

Polypharmacy review is essential. Oesophageal dysmotility and gastroparesis are more common in the elderly and may confound GORD-related cough assessment.

🫘 Renal Impairment

Gabapentin: Requires significant dose reduction — eGFR 30–59: max 600 mg/day; eGFR 15–29: max 300 mg/day; eGFR <15 or HD: 300 mg after dialysis on dialysis days.

Pregabalin: eGFR 30–59: max 300 mg/day; eGFR 15–29: max 150 mg/day; eGFR <15: 75 mg/day.

Gefapixant: eGFR 15–29: 45 mg OD; eGFR <15 or haemodialysis: not recommended.

PPIs: No significant renal adjustment, but prolonged PPI use associated with CKD progression — use at lowest effective dose and reassess need.

Patients on haemodialysis may develop cough from fluid overload, metabolic acidosis, and dialysis-related factors. Pulmonary oedema should be excluded.

🫁 Hepatic Impairment

Gefapixant: Child-Pugh A: no adjustment. Child-Pugh B–C: not recommended (no safety data, hepatically metabolised).

PPIs: Esomeprazole — avoid in severe hepatic impairment (Child-Pugh C, max 20 mg/day). Omeprazole/pantoprazole: use with caution.

Gabapentin: Not hepatically metabolised — no dose adjustment. Preferred neuromodulator in hepatic impairment.

Amitriptyline: Use with caution — hepatically metabolised; increased risk of sedation and cardiac effects in liver disease.

Ascites may cause diaphragmatic splinting and cough. Hepatopulmonary syndrome may present with cough and hypoxia in advanced liver disease.

🛡️ Immunocompromised

Expanded differential: In immunocompromised patients (HIV, transplant recipients, biologic therapy, chemotherapy), chronic cough requires a broader differential including opportunistic infections (Pneumocystis jirovecii, CMV, Aspergillus, NTM), drug-induced pneumonitis, and malignancy.

HIV: Chronic cough in HIV may indicate TB, PJP, or lymphoma. CD4 count and viral load guide the differential. TB screening is essential (Mantoux/IGRA).

Post-transplant: Consider CMV pneumonitis, Aspergillus, drug-induced cough (sirolimus/everolimus-associated pneumonitis).

Biologic therapy: Rituximab, methotrexate — drug-induced pneumonitis presents with cough and dyspnoea.

This guideline focuses on immunocompetent adults. Immunocompromised patients with chronic cough should be managed jointly with infectious diseases and respiratory specialists. Early CT chest and bronchoscopy with BAL are often indicated.

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Health Considerations

Chronic cough in Aboriginal and Torres Strait Islander peoples carries particular significance due to a disproportionately higher burden of chronic respiratory disease, delayed diagnosis, and barriers to specialist access. The following considerations are essential for culturally safe, evidence-based care.

Epidemiological Context

Bronchiectasis prevalence: Aboriginal and Torres Strait Islander children and adults have among the highest rates of bronchiectasis globally — up to 10 times the non-Indigenous Australian rate. Chronic wet/productive cough in an Indigenous child or young adult should always prompt consideration of bronchiectasis (HRCT, sputum culture).
Chronic suppurative lung disease (CSLD): Common in remote and very remote communities, particularly in the Northern Territory, Cape York, and Kimberley regions. Often underdiagnosed.
Post-infectious cough and pertussis: Higher rates of pertussis (whooping cough) in some communities due to lower vaccination coverage. Post-infectious cough may be protracted.
Environmental exposures: Wood smoke from indoor cooking/heating in remote communities, dust (red dust in central Australia), and overcrowded housing with poor ventilation contribute to chronic airway irritation and cough.
Smoking rates: Aboriginal and Torres Strait Islander adults smoke at approximately 2.5 times the rate of non-Indigenous Australians (AIHW 2023). Smoking cessation is a critical intervention for chronic cough.
Rheumatic heart disease: May cause pulmonary congestion and cough; ACE inhibitor therapy (for cardiac indications) may itself cause cough.

Barriers to Diagnosis and Management

Geographic access

Specialist respiratory services, spirometry, FeNO, induced sputum, and cough clinics are primarily available in metropolitan and large regional centres. Patients in remote communities may need to travel hundreds of kilometres for specialist assessment. Telehealth respiratory consultations (MBS items 99200–99215) are increasingly used and should be offered as a first option where appropriate.

Cultural safety

Cough is a common symptom that may not be prioritised against other health concerns. Clinicians should use culturally safe communication, involve Aboriginal and Torres Strait Islander health workers (A&TSIHWs), and understand community-specific health priorities. Shame and stigma may prevent presentation.

Diagnostic equipment

Spirometry is unavailable in many remote health centres. Point-of-care FeNO devices are not yet widely deployed. Portable spirometry and telehealth-supported lung function testing are emerging solutions. Ensure testing is culturally appropriate (explain the procedure, allow time, and have an A&TSIHW present).

Medication access

PBS medicines are available through community pharmacies and remote area health centres via Section 100 (S100) arrangements. Gefapixant (Lyfnua®) requires specialist initiation — accessible via telehealth respiratory consultation. Ensure continuity of supply in remote areas with intermittent pharmacy stock.

Otitis media and UACS

Chronic suppurative otitis media is highly prevalent in Aboriginal and Torres Strait Islander children and may contribute to chronic cough via upper airway inflammation and post-nasal drip. Assess ears in all children presenting with chronic cough.

Interdisciplinary care

Optimal management requires integration with Aboriginal Community Controlled Health Organisations (ACCHOs), A&TSIHWs, respiratory specialists (via telehealth), speech pathologists, and smoking cessation programs (Tackling Indigenous Smoking program). GP Management Plans (MBS item 721) and Team Care Arrangements (MBS item 723) support coordinated care.

⚠️

Key practice point: In Aboriginal and Torres Strait Islander patients presenting with chronic productive (wet) cough, always consider bronchiectasis — do not assume asthma or simple bronchitis. Early HRCT and specialist referral (via telehealth if necessary) can prevent progressive lung damage. The Lung Foundation Australia and RHDAustralia provide clinical resources and decision-support tools for clinicians managing chronic respiratory disease in Indigenous communities.

Quick Reference — Empiric Treatment Algorithm

Step 1: Suspected UACS

Intranasal corticosteroid (mometasone 200 µg OD) ± first-gen antihistamine/decongestant

2–4 weeks

If response → continue; if no response → Step 2

Step 2: Suspected asthma / eosinophilic bronchitis

Fluticasone propionate 250–500 µg BD via spacer

4–8 weeks

If response → continue at lowest effective dose; if no response → Step 3

Step 3: Suspected GORD

Esomeprazole 40 mg BD + lifestyle measures

≥8 weeks

Response may be delayed up to 3 months. Alginate add-on for breakthrough.

Step 4: Refractory cough

Speech pathology CST + gabapentin 300–600 mg BD (or pregabalin 150 mg BD)

≥8 weeks at target dose

Combine behavioural + pharmacological. Refer to cough clinic.

Step 5: Specialist-initiated

Gefapixant 45 mg BD (Lyfnua®) — PBS Authority Required

Review at 12 weeks

Respirator specialist initiation. Counselling re: taste disturbance (~60%).

📚 References

1. Morice AH, Millqvist E, Bieksiene K, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020;55(1):1901136. doi:10.1183/13993003.01136-2019
2. Gibson PG, Vertigan AE. Speech pathology for chronic cough: a new approach. Pulm Pharmacol Ther. 2009;22(2):159-162.
3. Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9853):1583-1589.
4. McGarvey L, Birring SS, Morice AH, et al. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet. 2022;399(10328):909-923.
5. Irwin RS, French CL, Chang AB, Altman KW; CHEST Expert Cough Panel. Classification of cough as a symptom in adults and management algorithms: CHEST guideline and expert panel report. Chest. 2018;153(1):196-209.
6. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
7. Chang AB, Upham JW, Masters IB, et al. Protracted bacterial bronchitis: the last decade and the road ahead. Pediatr Pulmonol. 2016;51(3):225-242.
8. Vertigan AE, Kapela SL, Ryan NM, Birring SS, Gibson PG. Effect of speech pathology management on chronic cough: a randomised controlled trial. Pulm Pharmacol Ther. 2016;40:58-64.
9. Lai K, Chen R, Lin J, et al. A prospective, multicenter survey on causes of chronic cough in China. Chest. 2013;143(3):613-620.
10. Mazzone SB, McGarvey L. Mechanisms and rationale for targeted therapies in reflex and central cough. Clin Chest Med. 2022;43(2):263-278.
11. Lung Foundation Australia. Bronchiectasis guidelines for Aboriginal and Torres Strait Islander health professionals. Milton QLD: Lung Foundation Australia; 2021.
12. Song WJ, Chang YS, Faruqi S, et al. The global epidemiology of chronic cough in adults: a systematic review and meta-analysis. Eur Respir J. 2015;45(5):1479-1481.
13. Department of Health and Aged Care. MBS Online — Medicare Benefits Schedule. Canberra: Australian Government. Available at: www.mbsonline.gov.au. Accessed January 2025.
14. Australian Government Department of Health. Pharmaceutical Benefits Schedule (PBS). Canberra: Commonwealth of Australia. Available at: www.pbs.gov.au. Accessed January 2025.
15. Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MDL, Pavord ID. Development of a symptom specific health status measure in patients with chronic cough: the Leicester Cough Questionnaire (LCQ). Thorax. 2003;58(4):339-343.